Associate
Emma's litigation experience includes federal district court matters, appeals before the Federal Circuit, and confidential arbitration proceedings. She is actively involved in all phases of litigation, including pre-litigation counseling as well as fact and expert discovery. Emma primarily litigates Abbreviated New Drug Application (ANDA) challenges, as well as cases related to medical device innovations and trade secrets.
While in law school, Emma was a student volunteer for the Indiana University Intellectual Property Law Clinic. She gained experience filing patent and trademark applications, participated in client counseling, and assisted in litigation matters. Emma also worked as a Milt Stewart Fellow in China, where she assisted in client counseling, protection of global trademark portfolios, and trademark enforcement.
Emma devotes time to pro bono matters. She represents honorably discharged veterans before the U.S. Court of Appeals for Veterans Claims and clients seeking asylum through the firm's partnership with Human Rights First.
Federal Circuit IP Blog
PTAB’s Implicit Claim Construction in Obviousness Analysis Constitutes Claim Construction, Even When Its Decision States It Did Not Construe Claims PTAB’s Implicit Claim Construction in Obviousness Analysis Constitutes Claim Construction, Even When Its Decision States It Did Not Construe Claims
March 21, 2024
Federal Circuit IP Blog
When to Consider Expert Testimony for Special Purpose Computer-Implemented Means-Plus-Function Claims When to Consider Expert Testimony for Special Purpose Computer-Implemented Means-Plus-Function Claims
October 20, 2023
At the PTAB Blog
Bringing Down the IPR Petition: Lack of Specification Citations Proves Fatal in Addressing Means-Plus-Function Claims Bringing Down the IPR Petition: Lack of Specification Citations Proves Fatal in Addressing Means-Plus-Function Claims
May 2, 2023
Prosecution First Blog
Federal Circuit Clarifies the Standard of Review for Invalidity Challenges Federal Circuit Clarifies the Standard of Review for Invalidity Challenges
January 13, 2023
At the PTAB Blog
Possible Defects Won’t Render Prior Art Inoperative Possible Defects Won’t Render Prior Art Inoperative
January 12, 2023
Articles
Patenting Treatments Involving Schedule I Substances Patenting Treatments Involving Schedule I Substances
October 17, 2022
Pharmaceutical OnlineDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.